Opti-DHA, from Douglas Laboratories®, is an omega-3 formula providing a novel ratio of DHA to EPA in an enteric-coated softgel for improved digestibility. Studies have shown that DHA, along with EPA, may play an important role in cardiovascular health. One landmark study, the GISSI-Prevenzione Trial, involved over 11,000 people who had already survived myocardial infarction. This was the first large-scale trial that showed supplementation of essential fatty acids (specifically fish oil) significantly lowered the risk of death by myocardial infarction and stroke. This important trial used supplements with a higher ratio of DHA to EPA, which is different from most fish oils available in the marketplace. Opti-DHA contains 450 mg of DHA and 150 mg of EPA in each two enteric-coated soft gelatin capsules. The oil used in Opti-DHA is the highest quality available and has gone through an extensive molecular distillation process to ensure the best possible product.
Content:
Two enteric-coated softgels contain:
Marine Lipid Concentrate 1000 mg.
Yielding
Docosahexaenoic Acid (DHA) 450 mg.
Eicosapentaenoic Acid (EPA) 150 mg.
Suggested Usage: Adults take 2 softgel capsules daily with meals, or as directed by physician.
